Celyad Oncology SA

CLYYF | $0.4138 -2.36% -1.88% 0

(0.0% 1d) (0.0% 1m) (-21.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-24.81% volume)
Earnings Calendar:
Market Cap: $ 10,975,932
http://www.celyad.com
Sec Filling | Patents | n/a employees

(BE) Celyad Oncology SA engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

ceiling cancer treatment t-cell

add to watch list Paper trade email alert is off

Celyad Oncology SA

CYADY | $0.6 0% 3K

n/a

(0.0% 1d) (0.0% 1m) (8.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (7.97% volume)
Earnings Calendar:
Market Cap: $ 15,914,836
https://www.celyad.com/
Sec Filling | Patents | 58 employees

(BE) founded in 2007, celyad is a clinical-stage biopharmaceutical company that leverages unique know-how in taking cell-based therapies from bench to phase iii, as well as the manufacturing and logistical infrastructure for such complex products. celyad builds it business model on partnering with prominent research institutions such as dartmouth college, and develops those programs from bench to commercial applications. the company is currently developing clinical programs in immuno-oncology, testing natural killer receptors t-cells (nkr-t cells) for cancer treatment. a unique approach that has the potential to target and destroy a vast majority of tumor types. celyad is listed on euronext brussels, euronext paris and on nasdaq (cyad).

t-cell

add to watch list Paper trade email alert is off

Nyxoah SA

NYXH | $10.92 5.92% 7.78% 19K

n/a

(0.0% 1d) (-24.0% 1m) (18.4% 1y) (0.0% 2d) (8.9% 3d) (8.0% 7d) (28.01% volume)
Earnings Calendar:
Market Cap: $ 312,988,876
https://www.nyxoah.com/
Sec Filling | Patents | 2021 employees

(BE) Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA).

add to watch list Paper trade email alert is off